muscles

Do muscle strength cut-offs used to define sarcopenia affect trajectories of disability progression in basic activities of daily living in older adults?

OBJECTIVE

This study aims to analyse trajectories of disability progression in basic activities of daily living (BADLs) as a function of sarcopenia, using different cut-off points for defining low muscle strength (LMS).

METHODS

A longitudinal study included 3,328 participants from the English Longitudinal...

🗓️ 2026-08-06
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreDo muscle strength cut-offs used to define sarcopenia affect trajectories of disability progression in basic activities of daily living in older adults?

Body Composition in Heart Failure: A Magnetic Resonance Imaging and Dual X-Ray Absorptiometry Assessment in the UK Biobank Study.

BACKGROUND

Metabolic and musculoskeletal abnormalities in patients with heart failure (HF) may not be fully captured by body mass index.

OBJECTIVES

Body composition was studied in participants with HF and matched control subjects in the UK Biobank Imaging Study, and findings were compared...

🗓️ 2026-08-05
📰 Publication: Jacc-Heart Failure
Read MoreBody Composition in Heart Failure: A Magnetic Resonance Imaging and Dual X-Ray Absorptiometry Assessment in the UK Biobank Study.

Preoperative swallowing muscle mass is associated with 1-year skeletal muscle loss and subsequent survival in lung cancer.

BACKGROUND & AIMS

Cancer cachexia is associated with systemic skeletal muscle loss and poor survival; however, early muscle changes preceding systemic muscle loss remain unclear. Therefore, this study aimed to determine whether tongue-complex muscle area (TCMA) can serve as an early...

🗓️ 2026-07-30
📰 Publication: Clinical Nutrition
Read MorePreoperative swallowing muscle mass is associated with 1-year skeletal muscle loss and subsequent survival in lung cancer.

Bile salt hydrolase-active bifidobacterium animalis improves sarcopenia via the gut microbiota-bile acid-FXR-FGF15 axis and its functional fermented milk preparation.

Sarcopenia is a major global health challenge associated with aging, and effective pharmacological treatments are lacking. This study investigated how bile salt hydrolase (BSH)-active probiotics alleviate sarcopenia through bile acid deconjugation and remodeling, activating the intestinal FXR-FGF15/19 signaling pathway, and...

🗓️ 2026-07-30
📰 Publication: Food Chemistry
Read MoreBile salt hydrolase-active bifidobacterium animalis improves sarcopenia via the gut microbiota-bile acid-FXR-FGF15 axis and its functional fermented milk preparation.

Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing.

BACKGROUND

Sarcopenia is a major contributor to frailty and mortality in ageing and obesity and is tightly linked to metabolic dysfunction. Imeglimin is a first-in-class oral hypoglycaemic agent targeting mitochondrial function; however, despite the central role of mitochondria in skeletal muscle...

🗓️ 2026-07-29
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing.

The Muscle-Liver Immunometabolic Axis in Liver Transplantation: A Decisive Role in Outcomes and Mechanisms.

Liver transplantation has transformed survival for end-stage liver disease, shifting clinical attention from acute rejection to longer-term vulnerability driven by metabolic dysfunction and loss of skeletal-muscle reserve. In this Review, we examine liver transplantation through the muscle-liver immunometabolic axis across...

🗓️ 2026-07-29
📰 Publication: International Journal Of Biological Sciences
Read MoreThe Muscle-Liver Immunometabolic Axis in Liver Transplantation: A Decisive Role in Outcomes and Mechanisms.

A C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Sarcopenia is a manifestation of musculoskeletal aging, yet no approved therapy is available. A major challenge is not the lack of potential interventions, but the difficulty of efficiently identifying which candidates should advance to aged-mammal validation. Sarcopenia is driven by...

🗓️ 2026-07-28
📰 Publication: Aging And Disease
Read MoreA C. elegans-to-Mouse Discovery Framework for Prioritizing Sarcopenia Interventions.

Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

Cancer cachexia is a life-threatening wasting syndrome that can be driven by tumor-derived GDF15 signaling through the brainstem-restricted receptor GFRAL. Despite its clinical importance, central genetic interventions targeting this axis remain limited. Here, we develop a potent antisense oligonucleotide (Gfral-ASO,...

🗓️ 2026-07-28
📰 Publication: Cell Reports Medicine
Read MoreTherapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice.

YAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

Sarcopenia, an age-related degenerative disease of skeletal muscle, is closely associated with osteoporosis and other bone disorders, partly due to dysregulated endocrine function of skeletal muscle. However, the specific cellular sources and molecular mechanisms driving this pathological secretory phenotype remain...

🗓️ 2026-07-27
Read MoreYAP1-Driven Pathogenic Fibro-Adipogenic Progenitors Secrete IL-6 and FGF21 to Mediate Muscle-Bone Crosstalk and Promote Bone Loss.

CXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

BACKGROUND

Sarcopenia is a progressive muscle-wasting condition driven in part by chronic inflammation; however, the specific inflammatory mediators that contribute to functional decline in humans and their responses to exercise remain poorly defined.

METHODS

We analyzed public ribonucleic acid (RNA) datasets to identify...

🗓️ 2026-07-23
📰 Publication: Journal Of Sport And Health Science
Read MoreCXCL2 is a modifiable driver of sarcopenic inflammation attenuated by exercise in older women: Integrated transcriptomic and experimental evidence.

Selective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

BACKGROUND

Skeletal muscle atrophy is a frequent comorbidity of metabolic disorders and chronic diseases, and despite its high prevalence, no pharmacological therapy is available, representing a major unmet clinical need. Adiponectin and its receptors are key regulators of skeletal muscle metabolism,...

🗓️ 2026-07-22
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSelective Small-Molecule AdipoR1 Agonist 3-Hydroxy Pterocarpan Salt (CDRI-1709S) Ameliorates Skeletal Muscle Atrophy.

Biological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

INTRODUCTION

Sarcopenia, the accelerated loss of muscle mass, strength and function with age, is associated with adverse health outcomes. DNA methylation accumulates across life and methylation clocks (which provide a measure of biological age) could potentially be used to predict individuals...

🗓️ 2026-07-19
📰 Publication: Aging Clinical And Experimental Research
Read MoreBiological age-acceleration in relation to muscle mass, strength and function: findings from the Hertfordshire Cohort Study.

Association between GDF-15 and sarcopenia progression in older adults: results from a population-based study.

BACKGROUND

Growth differentiation factor-15 (GDF-15), a stress-induced cytokine, has been implicated in pathways related to muscle degeneration, although findings regarding its association with sarcopenia remain heterogeneous. This study investigated the association between serum levels of GDF-15 and sarcopenia progression in community-dwelling...

🗓️ 2026-07-18
📰 Publication: Ebiomedicine
Read MoreAssociation between GDF-15 and sarcopenia progression in older adults: results from a population-based study.

Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Cancer cachexia significantly impacts the quality of life of cancer patients, predicting therapy response and survival. Cachexia prevalence and severity increases over the course of disease progression, affecting up to 80% of patients with metastatic cancer. Despite this, cachexia is...

🗓️ 2026-07-18
📰 Publication: Cancer And Metastasis Reviews
Read MoreUnderstanding cachexia and muscle dysfunction in the context of metastatic breast cancer.

Pre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

PURPOSE

Cancer cachexia is a life-threatening complication of advanced malignancies, driven by profound systemic metabolic reprogramming and anorexia. Insulin action is markedly impaired in patients with cancer and may contribute directly to cachexia pathogenesis. However, the interplay between weight loss, food...

🗓️ 2026-07-18
📰 Publication: Molecular Metabolism
Read MorePre-clinical cancer cachexia causes glucose hypermetabolism prior to overt weight loss.

Sex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Cancer cachexia is characterised by progressive skeletal muscle wasting and dysfunction, yet the early events that precede overt muscle wasting remain poorly defined. Here, we utilised a time-coursed C26 carcinoma model in male and female mice to define the pre-cachectic...

🗓️ 2026-07-17
📰 Publication: American Journal Of Physiology-Cell Physiology
Read MoreSex-divergent skeletal muscle remodeling emerges early in cancer cachexia.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!